<SEC-DOCUMENT>0001104659-20-024471.txt : 20200225
<SEC-HEADER>0001104659-20-024471.hdr.sgml : 20200225
<ACCEPTANCE-DATETIME>20200225073125
ACCESSION NUMBER:		0001104659-20-024471
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20200225
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200225
DATE AS OF CHANGE:		20200225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		20647365

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm206508-2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:insm="http://insmed.com/20200225">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_insm_insmed.com_20200225 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20200224_20200225 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001104506 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:EntityCentralIndexKey">0001104506</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="insm-20200225.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-02-24to2020-02-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-24</xbrli:startDate>
        <xbrli:endDate>2020-02-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt"><p style="margin: 0pt">&#160;</p></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_908_edei--DocumentType_c20200224__20200225_zee5VhCUeH6a"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The Securities Exchange Act of
1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b> <span id="xdx_90E_edei--DocumentPeriodEndDate_c20200224__20200225_zheuptvo4Hrj"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 25, 2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20200224__20200225_zKdGgSwD8m93"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:EntityRegistrantName">INSMED INCORPORATED</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified
in its charter)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20200224__20200225_zQTgoTYxJLE5"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Virginia</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityFileNumber_c20200224__20200225_zoGhlZ1DvRX1"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:EntityFileNumber">000-30739</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20200224__20200225_z1zczIE2Y4Pl"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:EntityTaxIdentificationNumber">54-1972729</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>(State
                                         or other jurisdiction</i></span></p>
                                                        <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>of
                                         incorporation)</i></span></p></td>
    <td style="vertical-align: bottom"><i>&#160;</i></td>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Commission</i></span></p>
                                                        <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>File
                                         Number)</i></span></p></td>
    <td style="vertical-align: bottom"><i>&#160;</i></td>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>(IRS
                                         Employer</i></span></p>
                                                        <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Identification
                                         No.)</i></span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt; width: 50%"><span id="xdx_905_edei--EntityAddressAddressLine1_c20200224__20200225_zpkDMA2zriE8"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:EntityAddressAddressLine1"><b>700 US Highway 202/206</b></ix:nonNumeric></span>
</td>
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt; width: 50%">&#160;</td></tr>
</table>


<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt; width: 50%"><span id="xdx_90C_edei--EntityAddressCityOrTown_c20200224__20200225_zFbafdq3mGI9"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:EntityAddressCityOrTown"><b>Bridgewater</b></ix:nonNumeric></span><b>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20200224__20200225_zEZfnaBD5HE3"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New
Jersey</ix:nonNumeric></span></b></td>
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt; width: 50%"><span id="xdx_900_edei--EntityAddressPostalZipCode_c20200224__20200225_zeUK0wkMJvIc"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:EntityAddressPostalZipCode"><b>08807</b></ix:nonNumeric></span></td></tr>
</table>


<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt; width: 50%"><i>(Address of principal executive offices)</i></td>
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt; width: 50%"><i>(Zip Code)</i></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number,&#160;including
area code: <b>(<span id="xdx_90B_edei--CityAreaCode_c20200224__20200225_zsShpjA6HOlj"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:CityAreaCode">908</ix:nonNumeric></span></b><b>) <span id="xdx_901_edei--LocalPhoneNumber_c20200224__20200225_zWPWWG0GzhMe"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:LocalPhoneNumber">977-9900</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Former name or former address, if changed
since last report.)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i>
General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span id="xdx_90B_edei--WrittenCommunications_c20200224__20200225_zhK456oIF6Fj" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160;
<span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span id="xdx_906_edei--SolicitingMaterial_c20200224__20200225_zlZFRXGm1jjf" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160; <span style="font: 10pt Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20200224__20200225_z8j5gBmYRRK9" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160; <span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20200224__20200225_zRpGDnbwkFih" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160; <span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt; border-image: none; width: 36%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; width: 1%; text-align: center"><b>&#160;</b></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt; border-image: none; width: 29%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; width: 2%; text-align: center"><b>&#160;</b></td>
    <td style="border: Black 1pt solid; padding: 2pt; border-image: none; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
<tr>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--Security12bTitle_c20200224__20200225_z0rvCmqI74ve"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:Security12bTitle">Common Stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; padding: 2pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--TradingSymbol_c20200224__20200225_z4chcrA1iLu8"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" name="dei:TradingSymbol">INSM</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; padding: 2pt; vertical-align: bottom">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--SecurityExchangeName_c20200224__20200225_zkiCbS4ORgf4"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR 230.405) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (17 CFR 240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company </span><span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20200224__20200225_zgNt6iQbwYR9"><ix:nonNumeric contextRef="From2020-02-24to2020-02-25" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt"><p style="margin: 0pt">&#160;</p></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 2.02.</b></td><td><span style="color: #212529"><b>Results of Operations and Financial Condition.</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 25, 2020, Insmed Incorporated
issued a press release regarding its financial results for the three months and fiscal year ended December 31, 2019. A copy of
this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02. The information contained herein, including
the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 10%; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b><br />
<b>No.</b></span></td>
    <td style="vertical-align: top; width: 2%; padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 88%; padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; padding-right: 3pt"><a href="tm206508d2_ex99-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></a></td>
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="text-align: left; padding-right: 3pt"><a href="tm206508d2_ex99-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Press Release by Insmed Incorporated on February 25, 2020.</span></a></td></tr>

<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left">104</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: left">Cover Page Interactive Date File (embedded within the Inline XBRL document).</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td colspan="2" style="padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>INSMED INCORPORATED</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td colspan="2" style="padding-right: 3pt; padding-left: 3pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 49%; padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif">Dated: February 25, 2020</span></td>
    <td style="width: 1%; padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="width: 6%; padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif">By: </span></td>
    <td style="border-bottom: Black 1pt solid; width: 44%; padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Christine Pellizzari</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td style="padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif">Christine Pellizzari</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td style="padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td style="padding-right: 3pt; padding-left: 3pt"><span style="font: 10pt Times New Roman, Times, Serif">Chief Legal Officer</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>










</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LdoOVNydDhVxigwRb6vLpLg1I61/j+RbWjfEEAjJOV+OED2xpIWpkOE4yzPYY91U2iPkWCKjPWNwpKt1AmHmeDHOs7a+XX9gSoHBwAz78hTurfNuHBYJyPEgHg3UBFScSAXTjYi+ekq2NAVab3QF2hawY2rYoNf86j7s9ZMs1a826YDsDNkEVF928htiqWLY0l0/iK8OsiwVUa+tSCyZbs035uY81TCvsA5ZrkP/HX0A1bZJCw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm206508d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><IMG SRC="tm2065082d2_ex99-1img01.jpg" ALT=""></TD><TD STYLE="vertical-align: middle; text-align: right; width: 50%"><B>Exhibit
                                         99.1</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><B>Insmed Reports Fourth Quarter and Full
Year 2019 Financial Results and Provides Business Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&mdash;ARIKAYCE<SUP>&reg;</SUP> (amikacin
liposome inhalation suspension) Total Revenue of $45.7 Million for the Fourth Quarter 2019 and $136.5 Million for the Full Year
2019&mdash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><I>&mdash;Company Provides Full-Year
2020 ARIKAYCE Revenue Guidance of $180 Million to $220 Million&mdash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><I>&mdash;Phase 2 WILLOW Study
of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis Achieves Primary and Key Secondary Endpoint&mdash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BRIDGEWATER, N.J., February 25, 2020 /PRNewswire/ &mdash; Insmed
Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and
rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a business
update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;2019 was a transformative year for Insmed as we evolved
into a commercial-stage organization and advanced our global infrastructure. I am incredibly proud of our team&rsquo;s performance
in the first full year of the ARIKAYCE U.S. launch, and we look forward to serving even more patients with the same level of dedication
as we prepare for a potential approval and commercial launch in Europe and regulatory filings in Japan,&rdquo; commented&nbsp;Will
Lewis, Chairman and Chief Executive Officer of Insmed. &ldquo;With our recent announcement of positive top-line Phase 2 data for
INS1007 in non-cystic fibrosis bronchiectasis, in addition to other meaningful advancements in our pipeline, we are well on our
way toward building a robust portfolio of therapies that address the unmet needs of small patient populations experiencing big
health problems.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fourth Quarter and Full-Year 2019 Financial Results </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
                                         revenue for the fourth quarter ended December 31, 2019 was $45.7 million, <FONT STYLE="background-color: white">comprising
                                         U.S. net sales of&nbsp;</FONT>$44.3 million<FONT STYLE="background-color: white">&nbsp;and
                                         ex-U.S. net sales of&nbsp;</FONT>$1.4 million. Total revenue for the full year 2019 was
                                         $136.5 million, <FONT STYLE="background-color: white">comprising U.S. net sales of&nbsp;</FONT>$132.1
                                         million<FONT STYLE="background-color: white">&nbsp;and ex-U.S. net sales of&nbsp;</FONT>$4.4
                                         million. This compares to total revenue of $9.8 million for the fourth quarter and full
                                         year 2018.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Cost
                                         of product revenues (excluding amortization of intangible assets) was $8.7 million for
                                         the fourth quarter of 2019, compared to $2.4 million for the fourth quarter of 2018.
                                         For the full year 2019, cost of product revenues was $24.2 million compared to $2.4 million
                                         in 2018. The increase in cost of product revenues is attributable to the increase in
                                         revenues. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">R&amp;D
                                         expenses were&nbsp;$32.6 million&nbsp;for the fourth quarter of 2019, compared to&nbsp;$39.9
                                         million&nbsp;for the fourth quarter of 2018. For the full year 2019, R&amp;D expenses
                                         were $131.7 million compared to $145.3 million in 2018. The decrease in R&amp;D is primarily
                                         due to the Company capitalizing inventory subsequent to the September 2018 U.S. Food
                                         and Drug Administration (FDA) approval of ARIKAYCE and capitalizing certain costs related
                                         to the investment in our long-term production capacity at Patheon in 2019.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Selling,
                                         general and administrative (SG&amp;A) expenses for the fourth quarter of 2019 were&nbsp;$50.2
                                         million, compared to&nbsp;$54.0 million&nbsp;for the fourth quarter of 2018. For the
                                         full year 2019, SG&amp;A expenses were $210.8 million, compared to $168.2 million in
                                         2018. The decrease in SG&amp;A in the fourth quarter is primarily due to a decrease in
                                         external expenses related to ARIKAYCE. The increase in SG&amp;A for the full year is
                                         primarily due to an increase in external expenses related to ARIKAYCE and a milestone
                                         owed in connection with amended agreements with the Cystic Fibrosis Foundation Therapeutics,&nbsp;Inc.
                                         (CFFT).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         the fourth quarter of 2019,&nbsp;Insmed&nbsp;reported a GAAP net loss of&nbsp;$53.0 million,
                                         or&nbsp;$0.59 per share, compared to a GAAP net loss of&nbsp;$91.6 million, or&nbsp;$1.19
                                         per share, for the fourth quarter of 2018. For the full year 2019, Insmed&nbsp;reported
                                         a GAAP net loss of&nbsp;$254.3 million, or&nbsp;$3.01 per share, compared to a GAAP net
                                         loss of&nbsp;$324.3 million, or&nbsp;$4.22 per share, in 2018.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Corporate Developments &amp; Program Highlights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Positive Top-Line Results from WILLOW Study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 3, 2020, Insmed announced positive top-line results
from the Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 in adults with non-cystic fibrosis
bronchiectasis. The study met both its primary endpoint of time to first pulmonary exacerbation over the 24-week treatment period
as well as a key secondary endpoint of reduction in the frequency of pulmonary exacerbations versus placebo. The Company plans
to advance INS1007 to Phase 3 development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ARIKAYCE  Lifecycle Management</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insmed continues to advance the post-approval confirmatory
clinical trial for ARIKAYCE in a front-line setting of patients with <I>Mycobacterium avium </I>complex (MAC) lung disease as
well as the development of an appropriate patient reported outcome (PRO) tool that will enable the assessment of therapies for
the treatment of nontuberculous mycobacterial (NTM) lung disease. Insmed plans to initiate both the confirmatory study and a study
to validate the PRO in the second half of 2020 and to run these studies in parallel, pending alignment with the FDA. The Company
also plans to advance into a separate registrational Phase 3 study in patients with NTM lung disease caused by <I>Mycobacterium
abscessus</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>INS1009 Advancement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insmed is advancing INS1009, a dry powder, inhaled treprostinil
prodrug formulation, for the potential treatment of pulmonary arterial hypertension. The Company plans to file an Investigational
New Drug application and initiate a Phase 1 study of INS1009 this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Global Expansion </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending the approval of our marketing authorization application
in Europe, Insmed anticipates a potential launch of ARIKAYCE in Germany by the end of 2020, followed shortly thereafter by the
UK. The Company plans to file for approval of ARIKAYCE in Japan in the first quarter of 2020. In addition, Insmed has engaged
DKSH Korea Ltd. to provide services to support an expanded access program on a named patient basis in South Korea.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Leadership Updates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recent senior leadership appointments include Fred Zussa, Senior
Vice President, Business Development, and Anjan Chatterjee, MD, MBA, MPH, Senior Vice President, Medical Affairs. Fred joins the
Company from Celgene Corporation, where he was a senior member of the Corporate Strategy and Development group. He is responsible
for sourcing, evaluating, and transacting business development activities for Insmed.&nbsp;Anjan joins Insmed from Boehringer
Ingelheim, where he most recently served as Corporate Vice President. He is responsible for expanding and leading the global Medical
Affairs function for ARIKAYCE as well as for our pipeline candidates as they advance toward late-stage development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Guidance and Balance Sheet </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2019,&nbsp;Insmed&nbsp;had cash and cash
equivalents of&nbsp;$487.4 million. The Company's total operating expenses for the fourth quarter of 2019 were $84.1 million and
for the full year of 2019 were $347.5 million. Adjusted operating expenses, as defined below, for the fourth quarter of 2019 were
$75.0 million and for the full year 2019 were $300.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company expects full-year 2020 revenues for ARIKAYCE to
be in the range of $180 million to $220 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company plans to invest in the following key activities
in 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>U.S. commercialization of ARIKAYCE;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">clinical
trial activities, including (a) the development of a PRO for NTM lung disease as well as the initiation of a study to validate
the PRO and, in parallel, a confirmatory clinical study of ARIKAYCE, (b) the advancement of INS1007 into a Phase 3 program in
patients with bronchiectasis, and (c) the advancement of INS1009 and our earlier-stage research pipeline; and</P>


</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD>expansion in Europe and Japan to support pre-commercial activities
                                         for ARIKAYCE in those regions and potential regulatory filings in Japan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of these activities,&nbsp;Insmed expects adjusted
operating expenses to be in the range of $340 million to $360 million for 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #323237">Insmed&nbsp;will host a conference call beginning
today at&nbsp;8:30 AM Eastern Time. Shareholders and other interested parties may participate in the conference call by dialing
(888) 317-6003 (domestic) or (412) 317-6061 (international) and referencing conference ID number 3317351. The call will also be
webcast live on the company's website at <U>www.insmed.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #323237">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #323237">A replay
of the conference call will be accessible approximately one hour after its completion through&nbsp;</FONT>March 3, 2020<FONT STYLE="color: #323237">&nbsp;by
dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing replay access code 10139238. A webcast of
the call will also be archived for 90 days under the Investors section of the Company's website at&nbsp;<U>www.insmed.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #323237"><B>Non-GAAP Financial
Measures </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #323237">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #323237">In addition
to&nbsp;the U.S.&nbsp;generally accepted accounting principles (GAAP) results, this earnings release includes adjusted operating
expenses, a non-GAAP financial measure, which&nbsp;Insmed&nbsp;defines as total operating expenses less stock-based compensation
expense, depreciation, amortization of intangibles</FONT> and certain milestones related to ARIKAYCE, which is payable under our
amended agreements with CFFT<FONT STYLE="color: #323237">. A reconciliation of this non-GAAP financial measure to its most directly
comparable GAAP financial measure is presented in the table attached to this press release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #323237">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #323237">Management believes
that this non-GAAP financial measure is useful to both management and investors in analyzing our ongoing business and operating
performance. Management believes that providing this non-GAAP information to investors, in addition to the GAAP results, allows
investors to view our financial results in the way that management views financial results.&nbsp;Management does not intend the
presentation of this non-GAAP financial measure to be considered in isolation or as a substitute for results prepared in accordance
with GAAP. In addition, this non-GAAP financial measure may differ from similarly named measures used by other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #323237">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ARIKAYCE<SUP>&reg;</SUP> (amikacin liposome inhalation
suspension)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARIKAYCE is the first and only FDA-approved therapy indicated
for the treatment of&nbsp;<I>Mycobacterium avium</I>&nbsp;complex (MAC) lung disease as part of a combination antibacterial drug
regimen for adult patients with limited or no alternative treatment options.&nbsp;ARIKAYCE is a novel, inhaled, once-daily formulation
of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to
hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE&trade; liposomal technology enables the delivery of amikacin
directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides. This approach prolongs
the release of amikacin in the lungs while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira<SUP>&reg;</SUP>&nbsp;Nebulizer
System manufactured by PARI Pharma GmbH (PARI).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PARI Pharma and the Lamira<SUP>&reg;</SUP>&nbsp;Nebulizer
System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">ARIKAYCE<SUP>&reg;</SUP>&nbsp;(amikacin
liposome inhalation suspension)&nbsp;is delivered by a novel inhalation device, the Lamira<SUP>&reg;</SUP>&nbsp;Nebulizer System,
developed by PARI. Lamira<SUP>&reg;</SUP>&nbsp;is a quiet, portable nebulizer that enables efficient aerosolization of liquid
medications, including liposomal formulations such as ARIKAYCE, via a vibrating, perforated membrane. Based on PARI's 100-year
history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms
and new pharmaceutical formulations that work together to improve patient care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About INS1007</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INS1007 is a small molecule, oral, reversible inhibitor of
dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible
for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone
marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory
mediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In chronic inflammatory lung diseases, neutrophils accumulate
in the airways and result in excessive active NSPs that cause lung destruction and inflammation. INS1007 may decrease the damaging
effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>IMPORTANT SAFETY INFORMATION FOR
ARIKAYCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="padding: 2pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">WARNING:
    RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="padding: 2pt; border-right: Black 1pt solid; border-left: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="padding: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid">ARIKAYCE
    has been associated with an increased risk of respiratory adverse reactions, including hypersensitivity pneumonitis, hemoptysis,
    bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases.<BR>
    &nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Hypersensitivity Pneumonitis&nbsp;</B>has
been reported with the use of ARIKAYCE in the clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis,
pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated
with ARIKAYCE plus background regimen (3.1%) compared to patients treated with a background regimen alone (0%). Most patients
with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity
pneumonitis occurs, discontinue ARIKAYCE and manage patients as medically appropriate<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Hemoptysis&nbsp;</B>has been reported
with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE
plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). If hemoptysis occurs, manage
patients as medically appropriate<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Bronchospasm</B>&nbsp;has been
reported with the use of ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm,
dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients
treated with ARIKAYCE plus background regimen (28.7%) compared to patients treated with a background regimen alone (10.7%). If
bronchospasm occurs during the use of ARIKAYCE, treat patients as medically appropriate<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exacerbations of underlying pulmonary
disease</B>&nbsp;has been reported with the use of ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease
(reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis)
have been reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients
treated with background regimen alone (9.8%)<I>.</I>&nbsp;If exacerbations of underlying pulmonary disease occur during the use
of ARIKAYCE, treat patients as medically appropriate<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Ototoxicity&nbsp;</B>has been reported
with the use of ARIKAYCE in the clinical trials. Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and vertigo)
were reported with a higher frequency in patients treated with ARIKAYCE plus background regimen (17%) compared to patients treated
with background regimen alone (9.8%). This was primarily driven by tinnitus (7.6% in ARIKAYCE plus background regimen vs 0.9%
in the background regimen alone arm) and dizziness (6.3% in ARIKAYCE plus background regimen vs 2.7% in the background regimen
alone arm). Closely monitor patients with known or suspected auditory or vestibular dysfunction during treatment with ARIKAYCE.
If ototoxicity occurs, manage patients as medically appropriate, including potentially discontinuing ARIKAYCE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Nephrotoxicity</B>&nbsp;was observed
during the clinical trials of ARIKAYCE in patients with MAC lung disease but not at a higher frequency than background regimen
alone. Nephrotoxicity has been associated with the aminoglycosides. Close monitoring of patients with known or suspected renal
dysfunction may be needed when prescribing ARIKAYCE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Neuromuscular Blockade</B>: Patients
with neuromuscular disorders were not enrolled in ARIKAYCE clinical trials. Patients with known or suspected neuromuscular disorders,
such as myasthenia gravis, should be closely monitored since aminoglycosides may aggravate muscle weakness by blocking the release
of acetylcholine at neuromuscular junctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Embryo-Fetal Toxicity</B>: Aminoglycosides
can cause fetal harm when administered to a pregnant woman.&nbsp; Aminoglycosides, including ARIKAYCE, may be associated with
total, irreversible, bilateral congenital deafness in pediatric patients exposed&nbsp;<I>in utero</I>. Patients who use ARIKAYCE
during pregnancy, or become pregnant while taking ARIKAYCE, should be apprised of the potential hazard to the fetus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contraindications</B>: ARIKAYCE
is contraindicated in patients with known hypersensitivity to any aminoglycoside.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Most Common Adverse Reactions</B>:
The most common adverse reactions in Trial 1 at an incidence &#8805;5% for patients using ARIKAYCE plus background regimen compared
to patients treated with background regimen alone were dysphonia (47% vs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis
(18% vs 13%), ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%), musculoskeletal pain (17% vs 8%), fatigue and asthenia
(16% vs 10%), exacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10%
vs 8%), headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%), change in
sputum (5% vs 1%), and chest discomfort (5% vs 3%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Drug Interactions</B>: Avoid concomitant
use of ARIKAYCE with medications associated with neurotoxicity, nephrotoxicity, and ototoxicity. Some diuretics can enhance aminoglycoside
toxicity by altering aminoglycoside concentrations in serum and tissue. Avoid concomitant use of ARIKAYCE with ethacrynic acid,
furosemide, urea, or intravenous mannitol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Overdosage</B>: Adverse reactions
specifically associated with overdose of ARIKAYCE have not been identified. Acute toxicity should be treated with immediate withdrawal
of ARIKAYCE, and baseline tests of renal function should be undertaken. Hemodialysis may be helpful in removing amikacin from
the body. In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about
effective treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>U.S. INDICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">LIMITED POPULATION: ARIKAYCE<SUP>&reg;</SUP>&nbsp;is
indicated in adults, who have limited or no alternative treatment options, for the treatment of&nbsp;<I>Mycobacterium avium</I>&nbsp;complex
(MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures
after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness
data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options<I>.&nbsp;</I>This
drug is indicated for use in a limited and specific population of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This indication is approved under
accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures)
by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification
and description of clinical benefit in confirmatory trials<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><U>Limitation of Use</U>:&nbsp;</B>ARIKAYCE
has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures
after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for
patients with non-refractory MAC lung disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Patients are encouraged to report
negative side effects of prescription drugs to the FDA. Visit&nbsp;<B><U>www.fda.gov/medwatch</U></B>, or call 1&#45;800&#45;FDA&#45;1088.
You can also call the Company at 1-844-4-INSMED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Please see&nbsp;</B></FONT><B><U>Full&nbsp;
Prescribing Information</U><FONT STYLE="background-color: white">.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Insmed</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insmed Incorporated is a global biopharmaceutical company on
a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE<SUP>&reg;
</SUP>(amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment
of refractory <I>Mycobacterium avium</I> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult
patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause
severe and permanent lung damage. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor
of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and
INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more information, visit <U>www.insmed.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements that
involve substantial risks and uncertainties. &quot;Forward-looking statements,&quot; as that term is defined in the Private Securities
Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words
herein such as &quot;may,&quot; &quot;will,&quot; &quot;should,&quot; &quot;could,&quot; &quot;would,&quot; &quot;expects,&quot;
 &quot;plans,&quot; &quot;anticipates,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;predicts,&quot;
 &quot;intends,&quot; &quot;potential,&quot; &quot;continues,&quot; and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) may identify forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The forward-looking statements in this press release are based
upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which
may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from
the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements.
Such risks, uncertainties and other factors include, among others, the following: failure to successfully commercialize or maintain
U.S. approval for ARIKAYCE, the Company's only approved product; uncertainties in the degree of market acceptance of ARIKAYCE
by physicians, patients, third-party payors and others in the healthcare community; the Company's inability to obtain full approval
of ARIKAYCE from the FDA, including the risk that the Company will not timely and successfully complete the study to validate
a PRO tool and complete the confirmatory post-marketing study required for full approval; inability of the Company, PARI or the
Company's other third party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira<SUP>&reg;</SUP>&nbsp;Nebulizer
System; the Company's inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable
prices for ARIKAYCE; development of unexpected safety or efficacy concerns related to ARIKAYCE; inaccuracies in the Company's
estimates of the size of the potential markets for ARIKAYCE or in data the Company has used to identify physicians; expected rates
of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company's inability
to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure
for distribution of ARIKAYCE; failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population;
risks that the full set of data from the WILLOW study will not be consistent with the top-line results of the study; failure to
successfully conduct future clinical trials for ARIKAYCE and the Company's product candidates, including due to the Company's
limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and
the Company's inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary
for regulatory approval; risks that the Company's clinical studies will be delayed or that serious side effects will be identified
during drug development; failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S. or for
the Company's product candidates in the U.S.,&nbsp;Europe,&nbsp;Japan&nbsp;or other markets, including the United Kingdom as a
result of its recent exit from the European Union; failure of third parties on which the Company is dependent to manufacture sufficient
quantities of ARIKAYCE or the Company's product candidates for commercial or clinical needs, to conduct the Company's clinical
trials, or to comply with laws and regulations that impact the Company's business or agreements with the Company; the Company's
inability to attract and retain key personnel or to effectively manage the Company's growth; the Company's inability to adapt
to its highly competitive and changing environment; the Company's inability to adequately protect its intellectual property rights
or prevent disclosure of its trade secrets and other proprietary information and costs associated with litigation or other proceedings
related to such matters; restrictions or other obligations imposed on the Company by its agreements related to ARIKAYCE or the
Company&rsquo;s product candidates, including its license agreements with PARI and AstraZeneca AB, and failure of the Company
to comply with its obligations under such agreements; the cost and potential reputational damage resulting from litigation to
which the Company is or may become a party, including product liability claims; the Company&rsquo;s limited experience operating
internationally; changes in laws and regulations applicable to the Company's business, including any pricing reform, and failure
to comply with such laws and regulations; inability to repay the Company's existing indebtedness and uncertainties with respect
to the Company's ability to access future capital; and delays in the execution of plans to build out an additional FDA-approved
third-party manufacturing facility and unexpected expenses associated with those plans.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company may not actually achieve the results, plans, intentions
or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve
risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For
additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed
in Item 1A, &quot;Risk Factors,&quot; in the Company's Annual Report on Form 10-K for the year ended&nbsp;December 31, 2019&nbsp;and
any subsequent Company filings with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company cautions readers not to place undue reliance on
any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation,
except as specifically required by law and the rules of the Securities and Exchange Commission, to publicly update or revise any
such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may
be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Financial Statements and Reconciliation
Follow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Split-Segment; Name: a2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INSMED INCORPORATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Net Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Three Months Ended <BR>
    December 31,</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Twelve Months Ended <BR>
    December 31,</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>2019</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>2019</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left">Revenues, net</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">45,708</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,835</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">136,467</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,835</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Cost of product revenues (excluding amortization of
    intangible assets)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,706</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,423</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,212</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,423</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 8pt">Gross profit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37,002</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,412</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">112,255</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,412</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,630</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39,925</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">131,711</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">145,283</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Selling, general and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,206</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,960</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">210,796</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">168,218</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 4pt">Amortization of intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,248</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,249</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,993</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,249</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 8pt">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">84,084</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">95,134</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">347,500</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">314,750</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(47,082</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(87,722</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(235,245</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(307,338</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,042</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,831</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,921</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,341</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,348</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(27,705</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,472</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on extingushment of debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,209</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other (expense) income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(276</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">52</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(531</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">602</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8pt">Loss before income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(52,664</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(91,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(253,560</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(324,076</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">324</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">67</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">777</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">201</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(52,988</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(91,573</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(254,337</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(324,277</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.59</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.19</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3.01</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4.22</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average basic and diluted common shares outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">89,466</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">77,096</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">84,560</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">76,889</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>INSMED INCORPORATED</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Consolidated Balance
Sheets</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(in thousands, except par value and share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2019</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2018</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">487,429</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">495,072</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Accounts receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,232</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,515</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,313</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,032</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 4pt">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,220</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,327</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">555,194</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">518,946</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Intangibles, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,682</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">58,675</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Fixed assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60,180</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,636</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance lease right-of-use assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,256</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease right-of-use assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,673</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,314</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,299</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">742,299</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">604,556</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and shareholders' equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,184</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,741</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,375</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38,254</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,140</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,208</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Finance lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,221</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Operating lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,040</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 4pt">Other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">280</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,529</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">85,240</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">79,732</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt, long-term</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">335,940</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">316,558</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance lease liabilities, long-term</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,529</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liabilities, long-term</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29,308</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other long-term liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,608</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">480,625</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">396,290</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Shareholders' equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -4pt; font: 10pt Times New Roman, Times, Serif; padding-left: 8pt">Common stock, $0.01 par value; 500,000,000 authorized
    shares, 89,682,387 and 77,307,521 issued and outstanding shares at December 31, 2019 and 2018, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">897</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">773</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,797,286</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,489,664</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,536,499</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,282,162</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 4pt">Accumulated other comprehensive loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(9</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total shareholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">261,674</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">208,266</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total liabilities and shareholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">742,299</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">604,556</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>INSMED INCORPORATED</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Reconciliation
of GAAP to Non-GAAP Results</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(in thousands) (unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Twelve Months Ended</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2018</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2018</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left">Total operating expenses - GAAP</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">84,084</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">95,134</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">347,500</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">314,750</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8pt">Stock-based compensation expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,888</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,035</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(26,971</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(26,240</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 8pt">Depreciation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,939</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(925</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,188</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,577</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 8pt">Amortization of intangibles</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,248</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,249</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,993</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,249</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 8pt">CFFT milestone payments</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,249</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Adjusted operating expenses - Non-GAAP</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">75,009</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">86,925</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">300,099</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">283,684</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Argot Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Laura Perry or Heather Savelle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(212) 600-1902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>insmed@argotpartners.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mandy Fahey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Director, Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insmed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(732) 487-7468</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">amanda.fahey@insmed.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>insm-20200225.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWa+GibPtzp5xWekhuWhwbZlKDywnYFelfSVbr6RmcQUK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:insm="http://insmed.com/20200225" elementFormDefault="qualified" targetNamespace="http://insmed.com/20200225">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://insmed.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="insm-20200225_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="insm-20200225_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>insm-20200225_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>insm-20200225_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://insmed.com/role/Cover" xlink:href="insm-20200225.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://insmed.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2065082d2_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2065082d2_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  _ )$# 2(  A$! Q$!_\0
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M2--3P_XZ"O\ V%HGC?1-<C?Q*'5EC!\43&!2CEDDD:-HZ_1+]M']A;XJ3?\
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(Q20HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>7
<FILENAME>0001104659-20-024471-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-024471-xbrl.zip
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M*146.;9987&V).%8Q6AXTW'/W=9*P'>,FK@%-E>5LG/YQPJG@T=XU/7RI=-
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M,MHF1%<%A A@#6"D4J/%?.:_;UGBW3P6T"8/2?D>>@\KH-XM,CVVV^0 XH
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MEDOJ-<1(JOW0L8V3G,2EI:N$8AHE.*T7@K3=4^\/<<;,0/,U/CWZ,$@:9M*
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M,E3Q%83WD3$0^6M,Y!Z%J-1'B@C-'"4(]F-K(/<WJ#<G'HVHX(<SRKG+^(@
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M+NO7'Z/Q5SW&>]ARD6O#0%UD 3PFJ"ED,Z1FMHQM[X'=^AB*KCM$4-)CU*4
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M*?R]: B=_O0 #C#6&@9M+=L$$L0X$=]0D5/A: MDPHDHD@06'!.+,%@O:A;
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M>YS(7C!)_Y!)O+F(RF,>[Y4)0F 2ESD4YT1]ZG8V-X0&6D O-#'R1#D,!$^
M+5WD?+$NW^@C>HOW1AF8&=P[7S(6)AM26WB4;)A)N216TOA 1SY]0N:];N>_
M%$6$;N__5K?S0^@$HCT8];,G\GH W,,J0ZQ9WLP-HL(5/*H64<*3G63*@HO'
MBZN QJR;)=*!N<2;C.#'>). P<%TL-G'0SX).QL!6]"\M-!\S&&AO:^\EBO'
M^H :K)<KL$)QN0]>VJ>([69:5.K5.-9<TD5:0M$2HXS&OO@?]E&Z;=JL@/[2
M5"VCY>6P.N$]TY4569<.87X6&EPE2"7PHF4;W+IH2$2F#<+E4I_/L4W5@BF)
MC&#8I85FKBOOB,J"+JP+XPN"\F:J.#@P$(9U0Y2N,5BV,)>+&:PF8F41]U;'
M2P[S&2K6*K%RN!U&")*7J3V^MB@'B2-QK1IY"UV%Z$04"J&4*BA1\PE4@G7.
M&2(OU4WY%&YXT.HQB_(.C(9PF8BE4$3!U4&'-JF+\OF$.K&\22!C%4'B"CZU
M1J\%E"$3E@&T $<ML92/BL2\5=F#C%T7ZP%:U]X1&0O3E&MXDT 43@0#10&:
MINRUJ$D,^;.Z)_D!%#DV)U+;_ 47J;F($#V\W&YN^ 'VCI@A[GH\VQ(C?#SA
MWCZZ[1T1$-"0($5(,GK#E=@FB,#!KU296S#@;Q-V(,P8H9:0IV."'6"03ASO
M5K/D2%/P3(I-5,<05S  A 14^+>>]4ER>$\'$?H4O=_&8?'"I?U9N#[!PA5X
M\[S("H[=L"SJ%H>&GA_Q;9TGWK$T[J''7=H:KMTI>U\3&OCB.0BWC.WP#->/
M=T%\\)EN^$^97M,SO41F;'R+[BBK FE0'^WG]E+" "9KIE/1K[%YRSF%+SNO
M0)?)%PW*FLZ9$&*E.]?:LM-9*96]!%.G[HWG<LL3\GH>5@C7&76\"\3SSFM6
M*^9? _-^"8C7SG?V/2"SN('7&'FOS72[FI+-*#E#NR>#?#ZN)CIN=V3T(H\;
M!X ,ZS#2CXA>+6 1HXU$BN<8PQJ8_8E9<"6CVKH?U4)H%!& (SLB5$],,\[7
MC]>52KS"F7^)2JRJ2GIZD[8ZZ$C(B^2[,HK<]'&_AZ-L \-D1 C\!^\/$A9W
M<N1+K,1]<;0E-BF&"+[%=@-"5A$$U^2;QI%XU3@R_/="B;SW[W.;)CKS-1T9
MI_Y$QI\@,OZHNR>-VO%%Z?JF_L+;,3]G<!V))3H-<C61(A!)C9\]RKQ-AMQW
M+]B7H]&V/"*W;_1@UZOCGDC'R]R#=T5&X(&-,0?*/,\N<B=- AOFEG#_ I#<
MBWL=-C=$DJ%GP2 )#_?<CLWH,S'6MR-83B2?86_P6P5Z0+M8H ]B6FQ%<*\/
MER-???=?$3:_GIMK"*%])4WGWWW+(T(-6#0BWB.Y8+L8BIO6("4?6O;=YWHX
M+* WE?P$8DF_.ZE)GD3E#@/W+B*]*W!Z]/D9,_I?8%@?XIKD[^)8*.OWQ?]'
M=J_GG2S<_+7"HZ2%SD@;F^A2OAZ!O6^MUR^,49?;B:7_[,1^^4YL*24)_JYQ
MAS[[%R(\VQA*$Q"_!ZNXY.]"RAW>RSHC[YKY^'<HD:^#HP=#.>T_E,X[/_+M
MW<%A]LRP+[]=#(U*Y]N MOOU9O;IS#EKJ[6LFGSXN]Z\?6A5JZ6'KY??_KZL
M5K2!4[MU'B^KZ>'SU=U=7KW1Z-7C;?GTX>KVHN^<NFJI>](EE9-+OHO__OX]
MWV[8)X?]TO-NKG/=8ZV+WLGAW=?A5;5]TD[='!XU]$;I^_7#'?V;//[4+DK?
M<#/USY'6P?T[C=W9%ZU<]F&7YW^<<Q7GM.Q=A5<N'JO?CO):KN/2G[=G=XJI
M).EI[I+3_K<;_+?;* ]_-+F2RO3N<NIU^8F7,C_8XU7RY+M24IL_OI;[!P<>
M2_X?4$L#!!0    ( .P[65!=L>/!A3P  +\- @ 5    =&TR,#8U,#AD,E]E
M>#DY+3$N:'1M[7UI4R/'LNAW(O@/=;GV'(AH--J784Q<L=E<P\ #Q@Z_+R]*
MK9+4GE:WW N,_.M?9E95+U(+)) 8@?K>..<PDKJK*C,K]^7S;W>7%X?;6Y]_
M.VV?P/\R_+_/=^=W%Z>'GS_*_X5O/ZJO/Q]=G?S%;N_^NCC]9:?G.L$G5BJ.
M G9G#87/OH@'=N,.N6/(#PQV*SRKMP,/PJ/7^KDA]_J6\XD5=PX_.!U_=/#Y
MX[7\R5W[Z.*4'9]>7%RW3T[.O_SZRTYQA_Y]>]T^UO]></D#)A?<#]P1+!K]
ML^,&@3ND3QZL;C# =Q5_WCG\?'>CE[@77F"9W-[GMM6''<,;#E@@O@?Z@[]#
M/[!Z8SSAY[L3_9AZ7:WX<_K7MN@%\/[SRU_9[<WQ+SO!L%RLUXK-<K?\_\3W
M5FN_9 W[Q5+A[U%_A[4O[G[9V4$DG!PFWCVYI:'5[=HBO8YG]0=!=*H:'>KH
M\/3[P.I8@<+Q//_7:A5*GS\>R3T@%=S=X-^(I F4+HH+@#K\M)C>MBF<0'CJ
M,\OI"GIGH68Y4X3RTH7E?Q?*\.Y,%!T=GCO^4'39C1BY7N"S,S?T@@'[/R'W
M8(^,.UUV%MKV]M9?@GNL7"RUV)GE<,>TN T/^:$-#^&OKCWWWNK"QHY"WW*$
M[[.OHRX/A(3KDHZ3!<>EPRQ[D<_GAQ^&7>X/#MHWY[^W_SH^_7S[]?KP@R?Z
ML#3^R7;YT/K&3<O9WK*MD>N[0\$L9\!M'EBNP_S0'PG'AS_WV)T;$/SNA1,*
MYO;83]5:H<$N+=O&G_9<CP4#,8D- C\"^Z=2I5ZH3?\<,,404=M;^%.UW\\?
MS]\8!A353A'M-"Z.W>&(.^.8^A $^QH$Y2+3R(I@_6MH=8%\)=!+S6($Q,!E
M/Y7+T;]7 ;RGSO7#P'@]X+Y@9?;G^<7%U9_L-@B[X^TM@-#YEUL0%@T@8W8-
M5 P/^L!N@22_N,[^\1B$@@G\H..YO@4WWW,=<V ),^#XSS;^?0^[O?8LV->8
M*/=W,8:]FJ[3Q4].G>[(M9S@'0![Y_#HYOSDU],_VW>G-P;[4OC?@L'.1,<+
M\:#EFL&('C]>W\#[_ ?+$Q^9.C:3/'A[Z]PQ70_X,+#-+MO]POTN_^<3H.!R
MSV"<]6VW TRC8[FC ?>&W!0A24AFJDL 1,Q!3OJ^(N? XXX/O&%(S,&V$!>
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ME?DFQLR/DL"2RP%W42X0K3UZTLX=DR\Y<WF?P?)^"/L':UUT7'D^[6B"#QT
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MR['$,Y$_2G:R)@J#,MI\E%V6/U#)?QW+Q0H,F=T-)X2;"&P*O:^H!ZF"9<4
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ME78@>Q,K7U<RPY0(!OMAJ#[8L7>*YG.@'@.4(E17U4GHXVP22>L9(]/D_+7
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M^ IKLB/L?#RZ.OF+5(C?[BXOX(__#U!+ 0(4 Q0    ( .P[65!4I+::10,
M (D,   1              "  0    !I;G-M+3(P,C P,C(U+GAS9%!+ 0(4
M Q0    ( .P[65!$Y.I4_ H  -^'   5              "  70#  !I;G-M
M+3(P,C P,C(U7VQA8BYX;6Q02P$"% ,4    " #L.UE0.7[!.E0'   P60
M%0              @ &C#@  :6YS;2TR,#(P,#(R-5]P<F4N>&UL4$L! A0#
M%     @ [#M94%W7<T_Y$@  1W   !$              ( !*A8  '1M,C V
M-3 X+3)?.&LN:'1M4$L! A0#%     @ [#M94%VQX\&%/   OPT" !4
M         ( !4BD  '1M,C V-3 X9#)?97@Y.2TQ+FAT;5!+!08     !0 %
+ $<!   *9@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm206508-2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="insm-20200225.xsd" xlink:type="simple"/>
    <context id="From2020-02-24to2020-02-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2020-02-24</startDate>
            <endDate>2020-02-25</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-02-24to2020-02-25">0001104506</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-02-24to2020-02-25">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-02-24to2020-02-25">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-02-24to2020-02-25">2020-02-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-02-24to2020-02-25">INSMED INCORPORATED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-02-24to2020-02-25">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-02-24to2020-02-25">000-30739</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-02-24to2020-02-25">54-1972729</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-02-24to2020-02-25">700 US Highway 202/206</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2020-02-24to2020-02-25">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-02-24to2020-02-25">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-02-24to2020-02-25">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-02-24to2020-02-25">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-02-24to2020-02-25">977-9900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-02-24to2020-02-25">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-02-24to2020-02-25">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-02-24to2020-02-25">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-02-24to2020-02-25">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-02-24to2020-02-25">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-02-24to2020-02-25">INSM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-02-24to2020-02-25">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-02-24to2020-02-25">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm206508-2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://insmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm206508-2_8k.htm">tm206508-2_8k.htm</File>
    <File>insm-20200225.xsd</File>
    <File>insm-20200225_lab.xml</File>
    <File>insm-20200225_pre.xml</File>
    <File>tm206508d2_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6636746496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 25, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 25,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INCORPORATED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">54-1972729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 US Highway 202/206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-9900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INSM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm206508-2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm206508-2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20200225_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20200225_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "insm-20200225.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "insm",
   "nsuri": "http://insmed.com/20200225",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm206508-2_8k.htm",
      "contextRef": "From2020-02-24to2020-02-25",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://insmed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm206508-2_8k.htm",
      "contextRef": "From2020-02-24to2020-02-25",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://insmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M\+L(6Z_-SOQCX[/@T,.ONQB^ %!+ P04    " #L.UE0F5R<(Q &  "<)P
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M7H(PK8>_R43]-<#JUV5?4$L#!!0    ( .P[65 +C]@#(0$  %<$   3
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M+G)E;'-02P$"% ,4    " #L.UE0)^B'#H(   "Q    $
M@ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .P[65#X*X@W[@
M "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( .P[65"97)PC$ 8  )PG   3              "  ;8"  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ [#M94&5P><V= @  DPL  !@
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9>&UL4$L%!@     *  H @ (   ,4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
